Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year High - Time to Buy?

Key Points

• New 52-week high: Xenon hit a high of $62.64 (last $59.71) on Monday with about 5.61 million shares traded, roughly a 46% move from the prior close of $41.94.
• Analyst sentiment is largely positive: two Strong Buy, 13 Buy and one Sell produce an average "Buy" rating and an average target price of $55.50, with individual targets as high as $66.
• Mixed fundamentals and insider activity: Xenon reported a Q4 EPS loss of ($1.31), missing estimates and projecting negative FY EPS (~-3.1), while the company has a ~$5.1B market cap; CEO Ian Mortimer sold 40,000 shares and insiders own ~4.07% as institutions hold ~95% of the stock.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $62.64 and last traded at $59.71, with a volume of 5611537 shares trading hands. The stock had previously closed at $41.94.

Analysts Set New Price Targets

A number of analysts recently issued reports on XENE shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Needham & Company LLC upped their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company a "buy" rating in a research report on Friday, February 27th. Jefferies Financial Group reissued a "buy" rating on shares of Xenon Pharmaceuticals in a report on Monday. Chardan Capital raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, November 19th. Finally, Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $55.50.

Xenon Pharmaceuticals Trading Up 46.1%

The stock's fifty day moving average price is $42.25 and its 200 day moving average price is $41.24. The stock has a market cap of $5.10 billion, a P/E ratio of -14.06 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same period in the prior year, the company earned ($0.84) EPS. On average, analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 40,000 shares of the firm's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the transaction, the chief executive officer directly owned 6,000 shares of the company's stock, valued at approximately $266,580. This trade represents a 86.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.07% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC boosted its stake in shares of Xenon Pharmaceuticals by 0.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company's stock valued at $243,124,000 after purchasing an additional 24,444 shares in the last quarter. Janus Henderson Group PLC raised its position in Xenon Pharmaceuticals by 3.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company's stock worth $183,110,000 after purchasing an additional 140,149 shares during the period. Wellington Management Group LLP lifted its stake in Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company's stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Braidwell LP boosted its position in Xenon Pharmaceuticals by 33.0% during the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company's stock valued at $112,837,000 after buying an additional 895,154 shares during the period. Finally, Capital International Investors boosted its position in Xenon Pharmaceuticals by 7.3% during the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company's stock valued at $153,058,000 after buying an additional 233,466 shares during the period. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.